The epidermal growth factor receptor and its ligands in cardiovascular disease

International Journal of Molecular Sciences

Volumn 14, Issue 10, 2013, Pages 20597-20613

  Makki, Nader ^a   Thiel, Kristina W ^a   Miller Jr , Francis J ^a,b  

^a UNIVERSITY OF IOWA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Atherosclerosis; Cardiac remodeling; EGF like ligands; EGFR; Vascular disease

Indexed keywords

CETUXIMAB; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; LAPATINIB; LIGAND; PANITUMUMAB; PERTUZUMAB; PROTEIN TYROSINE KINASE; TRASTUZUMAB; VASCULOTROPIN;

ACUTE CORONARY SYNDROME; ANGIOGENESIS; ANGIOPLASTY; ATHEROSCLEROSIS; BLOOD PRESSURE REGULATION; BLOOD VESSEL; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CONGESTIVE HEART FAILURE; DIABETES MELLITUS; DRUG MECHANISM; ENDOTHELIUM CELL; HEART DEVELOPMENT; HEART EJECTION FRACTION; HEART INJURY; HUMAN; NONHUMAN; PROTEIN FUNCTION; RESTENOSIS; REVIEW; SIDE EFFECT; SMOOTH MUSCLE FIBER; VASCULAR SMOOTH MUSCLE CELL;

ANIMALS; CARDIOVASCULAR DISEASES; HUMANS; LIGANDS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 84885907154     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms141020597     Document Type: Review

References (100)

1. Holbro, T.; Hynes, N.E. ErbB receptors: Directing key signaling networks throughout life. Annu. Rev. Pharmacol. Toxicol. 2004, 44, 195-217.
2. Hackel, P.O.; Zwick, E.; Prenzel, N.; Ullrich, A. Epidermal growth factor receptors: Critical mediators of multiple receptor pathways. Curr. Opin. Cell Biol. 1999, 11, 184-189.
3. Wetzker, R.; Bohmer, F.D. Transactivation joins multiple tracks to the ERK/MAPK cascade. Nat. Rev. Mol. Cell Biol. 2003, 4, 651-657.
4. Prenzel, N.; Zwick, E.; Daub, H.; Leserer, M.; Abraham, R.; Wallasch, C.; Ullrich, A. EGF receptor transactivation by G-protein-coupled receptors requires metalloproteinase cleavage of proHB-EGF. Nature 1999, 402, 884-888.
5. Prenzel, N.; Fischer, O.M.; Streit, S.; Hart, S.; Ullrich, A. The epidermal growth factor receptor family as a central element for cellular signal transduction and diversification. Endocr. Relat. Cancer 2001, 8, 11-31.
6. Andreev, J.; Galisteo, M.L.; Kranenburg, O.; Logan, S.K.; Chiu, E.S.; Okigaki, M.; Cary, L.A.; Moolenaar, W.H.; Schlessinger, J. Src and Pyk2 mediate G-protein-coupled receptor activation of epidermal growth factor receptor (EGFR) but are not required for coupling to the mitogen-activated protein (MAP) kinase signaling cascade. J. Biol. Chem. 2001, 276, 20130-20135.
7. Lin, S.Y.; Makino, K.; Xia, W.; Matin, A.; Wen, Y.; Kwong, K.Y.; Bourguignon, L.; Hung, M.C. Nuclear localization of EGF receptor and its potential new role as a transcription factor. Nat. Cell Biol. 2001, 3, 802-808.
8. Liao, H.J.; Carpenter, G. Role of the Sec61 translocon in EGF receptor trafficking to the nucleus and gene expression. Mol. Biol. Cell 2007, 18, 1064-1072.
9. Liao, H.J.; Carpenter, G. Regulated intramembrane cleavage of the EGF receptor. Traffic 2012, 13, 1106-1112.
10. Wilken, J.A.; Perez-Torres, M.; Nieves-Alicea, R.; Cora, E.M.; Christensen, T.A.; Baron, A.T.; Maihle, N.J. Shedding of soluble epidermal growth factor receptor (sEGFR) is mediated by a metalloprotease/fibronectin/integrin axis and inhibited by cetuximab. Biochemistry 2013, 52, 4531-4540.
11. Massague, J.; Pandiella, A. Membrane-anchored growth factors. Annu. Rev. Biochem. 1993, 62, 515-541.
12. Burgess, A.W. Epidermal growth factor and transforming growth factor alpha. Br. Med. Bull. 1989, 45, 401-424.
13. Peschon, J.J.; Slack, J.L.; Reddy, P.; Stocking, K.L.; Sunnarborg, S.W.; Lee, D.C.; Russell, W.E.; Castner, B.J.; Johnson, R.S.; Fitzner, J.N.; et al. An essential role for ectodomain shedding in mammalian development. Science 1998, 282, 1281-1284.
14. Hinkle, C.L.; Mohan, M.J.; Lin, P.; Yeung, N.; Rasmussen, F.; Milla, M.E.; Moss, M.L. Multiple metalloproteinases process protransforming growth factor-alpha (proTGF-alpha). Biochemistry 2003, 42, 2127-2136.
15. Yu, W.H.; Woessner, J.F., Jr.; McNeish, J.D.; Stamenkovic, I. CD44 anchors the assembly of matrilysin/MMP-7 with heparin-binding epidermal growth factor precursor and ErbB4 and regulates female reproductive organ remodeling. Genes Dev. 2002, 16, 307-323.
16. Suzuki, M.; Raab, G.; Moses, M.A.; Fernandez, C.A.; Klagsbrun, M. Matrix metalloproteinase-3 releases active heparin-binding EGF-like growth factor by cleavage at a specific juxtamembrane site. J. Biol. Chem. 1997, 272, 31730-31737.
17. Miettinen, P.J.; Berger, J.E.; Meneses, J.; Phung, Y.; Pedersen, R.A.; Werb, Z.; Derynck, R. Epithelial immaturity and multiorgan failure in mice lacking epidermal growth factor receptor. Nature 1995, 376, 337-341.
18. Sibilia, M.; Wagner, E.F. Strain-dependent epithelial defects in mice lacking the EGF receptor. Science 1995, 269, 234-238.
19. Threadgill, D.W.; Dlugosz, A.A.; Hansen, L.A.; Tennenbaum, T.; Lichti, U.; Yee, D.; LaMantia, C.; Mourton, T.; Herrup, K.; Harris, R.C.; et al. Targeted disruption of mouse EGF receptor: Effect of genetic background on mutant phenotype. Science 1995, 269, 230-234.
20. Kornblum, H.I.; Hussain, R.; Wiesen, J.; Miettinen, P.; Zurcher, S.D.; Chow, K.; Derynck, R.; Werb, Z. Abnormal astrocyte development and neuronal death in mice lacking the epidermal growth factor receptor. J. Neurosci. Res. 1998, 53, 697-717.
21. Sibilia, M.; Steinbach, J.P.; Stingl, L.; Aguzzi, A.; Wagner, E.F. A strain-independent postnatal neurodegeneration in mice lacking the EGF receptor. EMBO J. 1998, 17, 719-731.
22. Luetteke, N.C.; Phillips, H.K.; Qiu, T.H.; Copeland, N.G.; Earp, H.S.; Jenkins, N.A.; Lee, D.C. The mouse waved-2 phenotype results from a point mutation in the EGF receptor tyrosine kinase. Genes Dev. 1994, 8, 399-413.
23. Barrick, C.J.; Roberts, R.B.; Rojas, M.; Rajamannan, N.M.; Suitt, C.B.; O'Brien, K.D.; Smyth, S.S.; Threadgill, D.W. Reduced EGFR causes abnormal valvular differentiation leading to calcific aortic stenosis and left ventricular hypertrophy in C57BL/6J but not 129S1/SvImJ mice. Am. J. Physiol. Heart Circ. Physiol. 2009, 297, H65-H75.
24. Gassmann, M.; Casagranda, F.; Orioli, D.; Simon, H.; Lai, C.; Klein, R.; Lemke, G. Aberrant neural and cardiac development in mice lacking the ErbB4 neuregulin receptor. Nature 1995, 378, 390-394.
25. Lee, K.F.; Simon, H.; Chen, H.; Bates, B.; Hung, M.C.; Hauser, C. Requirement for neuregulin receptor erbB2 in neural and cardiac development. Nature 1995, 378, 394-398.
26. McBride, K.L.; Zender, G.A.; Fitzgerald-Butt, S.M.; Seagraves, N.J.; Fernbach, S.D.; Zapata, G.; Lewin, M.; Towbin, J.A.; Belmont, J.W. Association of common variants in ERBB4 with congenital left ventricular outflow tract obstruction defects. Birth Defects Res. A 2011, 91, 162-168.
27. Iwamoto, R.; Yamazaki, S.; Asakura, M.; Takashima, S.; Hasuwa, H.; Miyado, K.; Adachi, S.; Kitakaze, M.; Hashimoto, K.; Raab, G.; et al. Heparin-binding EGF-like growth factor and ErbB signaling is essential for heart function. Proc. Natl. Acad. Sci. USA 2003, 100, 3221-3226.
28. Hartmann, D.; de Strooper, B.; Serneels, L.; Craessaerts, K.; Herreman, A.; Annaert, W.; Umans, L.; Lubke, T.; Lena Illert, A.; von Figura, K.; Saftig, P. The disintegrin/metalloprotease ADAM 10 is essential for Notch signalling but not for alpha-secretase activity in fibroblasts. Hum. Mol. Genet. 2002, 11, 2615-2624.
29. Kato, M.; Inazu, T.; Kawai, Y.; Masamura, K.; Yoshida, M.; Tanaka, N.; Miyamoto, K.; Miyamori, I. Amphiregulin is a potent mitogen for the vascular smooth muscle cell line, A7r5. Biochem. Biophys. Res. Commun. 2003, 301, 1109-1115.
30. Dreux, A.C.; Lamb, D.J.; Modjtahedi, H.; Ferns, G.A. The epidermal growth factor receptors and their family of ligands: Their putative role in atherogenesis. Atherosclerosis 2006, 186, 38-53.
31. Stanic, B.; Pandey, D.; Fulton, D.J.; Miller, F.J., Jr. Increased epidermal growth factor-like ligands are associated with elevated vascular nicotinamide adenine dinucleotide phosphate oxidase in a primate model of atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 2012, 32, 2452-2460.
32. Gospodarowicz, D.; Hirabayashi, K.; Giguere, L.; Tauber, J.P. Factors controlling the proliferative rate, final cell density, and life span of bovine vascular smooth muscle cells in culture. J. Cell Biol. 1981, 89, 568-578.
33. Schreier, B.; Dohler, M.; Rabe, S.; Schneider, B.; Schwerdt, G.; Ruhs, S.; Sibilia, M.; Gotthardt, M.; Gekle, M.; Grossmann, C. Consequences of epidermal growth factor receptor (ErbB1) loss for vascular smooth muscle cells from mice with targeted deletion of ErbB1. Arterioscler. Thromb. Vasc. Biol. 2011, 31, 1643-1652.
34. Mazak, I.; Fiebeler, A.; Muller, D.N.; Park, J.K.; Shagdarsuren, E.; Lindschau, C.; Dechend, R.; Viedt, C.; Pilz, B.; Haller, H.; et al. Aldosterone potentiates angiotensin II-induced signaling in vascular smooth muscle cells. Circulation 2004, 109, 2792-2800.
35. Min, L.J.; Mogi, M.; Li, J.M.; Iwanami, J.; Iwai, M.; Horiuchi, M. Aldosterone and angiotensin II synergistically induce mitogenic response in vascular smooth muscle cells. Circ. Res. 2005, 97, 434-442.
36. Berk, B.C.; Brock, T.A.; Webb, R.C.; Taubman, M.B.; Atkinson, W.J.; Gimbrone, M.A., Jr.; Alexander, R.W. Epidermal growth factor, a vascular smooth muscle mitogen, induces rat aortic contraction. J. Clin. Invest. 1985, 75, 1083-1086.
37. Ushio-Fukai, M.; Griendling, K.K.; Becker, P.L.; Hilenski, L.; Halleran, S.; Alexander, R.W. Epidermal growth factor receptor transactivation by angiotensin II requires reactive oxygen species in vascular smooth muscle cells. Arterioscler. Thromb. Vasc. Biol. 2001, 21, 489-495.
38. Chen, C.H.; Cheng, T.H.; Lin, H.; Shih, N.L.; Chen, Y.L.; Chen, Y.S.; Cheng, C.F.; Lian, W.S.; Meng, T.C.; Chiu, W.T.; et al. Reactive oxygen species generation is involved in epidermal growth factor receptor transactivation through the transient oxidization of src homology 2-containing tyrosine phosphatase in endothelin-1 signaling pathway in rat cardiac fibroblasts. Mol. Pharmacol. 2006, 69, 1347-1355.
39. Yang, C.M.; Lin, M.I.; Hsieh, H.L.; Sun, C.C.; Ma, Y.H.; Hsiao, L.D. Bradykinin-induced p42/p44 MAPK phosphorylation and cell proliferation via Src, EGF receptors, and PI3-K/Akt in vascular smooth muscle cells. J. Cell Physiol. 2005, 203, 538-546.
40. Iwasaki, H.; Eguchi, S.; Marumo, F.; Hirata, Y. Endothelin-1 stimulates DNA synthesis of vascular smooth-muscle cells through transactivation of epidermal growth factor receptor. J. Cardiovasc. Pharmacol. 1998, 31, S182-S184.
41. Kawanabe, Y.; Masaki, T.; Hashimoto, N. Involvement of epidermal growth factor receptor-protein tyrosine kinase transactivation in endothelin-1-induced vascular contraction. J. Neurosurg. 2004, 100, 1066-1071.
42. Kanda, Y.; Mizuno, K.; Kuroki, Y.; Watanabe, Y. Thrombin-induced p38 mitogen-activated protein kinase activation is mediated by epidermal growth factor receptor transactivation pathway. Br. J. Pharmacol. 2001, 132, 1657-1664.
43. Jagadeesha, D.K.; Takapoo, M.; Banfi, B.; Bhalla, R.C.; Miller, F.J., Jr. Nox1 transactivation of epidermal growth factor receptor promotes N-cadherin shedding and smooth muscle cell migration. Cardiovasc. Res. 2012, 93, 406-413.
44. Eguchi, S.; Inagami, T. Signal transduction of angiotensin II type 1 receptor through receptor tyrosine kinase. Regul. Pept. 2000, 91, 13-20.
45. Ohtsu, H.; Dempsey, P.J.; Eguchi, S. ADAMs as mediators of EGF receptor transactivation by G protein-coupled receptors. Am. J. Physiol. Cell Physiol. 2006, 291, C1-C10.
46. Seals, D.F.; Courtneidge, S.A. The ADAMs family of metalloproteases: Multidomain proteins with multiple functions. Genes Dev. 2003, 17, 7-30.
47. Van Wart, H.E.; Birkedal-Hansen, H. The cysteine switch: A principle of regulation of metalloproteinase activity with potential applicability to the entire matrix metalloproteinase gene family. Proc. Natl. Acad. Sci. USA 1990, 87, 5578-5582.
48. Takaguri, A.; Shirai, H.; Kimura, K.; Hinoki, A.; Eguchi, K.; Carlile-Klusacek, M.; Yang, B.; Rizzo, V.; Eguchi, S. Caveolin-1 negatively regulates a metalloprotease-dependent epidermal growth factor receptor transactivation by angiotensin II. J. Mol. Cell Cardiol. 2011, 50, 545-551.
49. Miller, F.J., Jr.; Chu, X.; Stanic, B.; Tian, X.; Sharma, R.V.; Davisson, R.L.; Lamb, F.S. A differential role for endocytosis in receptor-mediated activation of Nox1. Antioxid. Redox Signal. 2010, 12, 583-593.
50. Stanic, B.; Katsuyama, M.; Miller, F.J., Jr. An oxidized extracellular oxidation-reduction state increases Nox1 expression and proliferation in vascular smooth muscle cells via epidermal growth factor receptor activation. Arterioscler. Thromb. Vasc. Biol. 2010, 30, 2234-2241.
51. Hsieh, H.L.; Lin, C.C.; Chan, H.J.; Yang, C.M. c-Src-dependent EGF receptor transactivation contributes to ET-1-induced COX-2 expression in brain microvascular endothelial cells. J. Neuroinflammation 2012, 9, 152.
52. Mehta, V.B.; Zhou, Y.; Radulescu, A.; Besner, G.E. HB-EGF stimulates eNOS expression and nitric oxide production and promotes eNOS dependent angiogenesis. Growth Factors 2008, 26, 301-315.
53. Zhou, Y.; Brigstock, D.; Besner, G.E. Heparin-binding EGF-like growth factor is a potent dilator of terminal mesenteric arterioles. Microvasc. Res. 2009, 78, 78-85.
54. Schreier, B.; Rabe, S.; Schneider, B.; Bretschneider, M.; Rupp, S.; Ruhs, S.; Neumann, J.; Rueckschloss, U.; Sibilia, M.; Gotthardt, M.; Grossmann, C.; Gekle, M. Loss of epidermal growth factor receptor in vascular smooth muscle cells and cardiomyocytes causes arterial hypotension and cardiac hypertrophy. Hypertension 2013, 61, 333-340.
55. Amin, A.H.; Abd Elmageed, Z.Y.; Partyka, M.; Matrougui, K. Mechanisms of myogenic tone of coronary arteriole: Role of down stream signaling of the EGFR tyrosine kinase. Microvasc. Res. 2011, 81, 135-142.
56. Chansel, D.; Ciroldi, M.; Vandermeersch, S.; Jackson, L.F.; Gomez, A.M.; Henrion, D.; Lee, D.C.; Coffman, T.M.; Richard, S.; Dussaule, J.C.; Tharaux, P.L. Heparin binding EGF is necessary for vasospastic response to endothelin. FASEB J. 2006, 20, 1936-1938.
57. Flamant, M.; Tharaux, P.L.; Placier, S.; Henrion, D.; Coffman, T.; Chatziantoniou, C.; Dussaule, J.C. Epidermal growth factor receptor trans-activation mediates the tonic and fibrogenic effects of endothelin in the aortic wall of transgenic mice. FASEB J. 2003, 17, 327-329.
58. Hao, L.; Du, M.; Lopez-Campistrous, A.; Fernandez-Patron, C. Agonist-induced activation of matrix metalloproteinase-7 promotes vasoconstriction through the epidermal growth factor-receptor pathway. Circ. Res. 2004, 94, 68-76.
59. Grossmann, C.; Freudinger, R.; Mildenberger, S.; Krug, A.W.; Gekle, M. Evidence for epidermal growth factor receptor as negative-feedback control in aldosterone-induced Na+ reabsorption. Am. J. Physiol. Renal Physiol. 2004, 286, F1226-F1231.
60. Larsen, A.K.; Ouaret, D.; El Ouadrani, K.; Petitprez, A. Targeting EGFR and VEGF(R) pathway cross-talk in tumor survival and angiogenesis. Pharmacol. Ther. 2011, 131, 80-90.
61. Chalothorn, D.; Moore, S.M.; Zhang, H.; Sunnarborg, S.W.; Lee, D.C.; Faber, J.E. Heparin-binding epidermal growth factor-like growth factor, collateral vessel development, and angiogenesis in skeletal muscle ischemia. Arterioscler. Thromb. Vasc. Biol. 2005, 25, 1884-1890.
62. Amin, A.H.; Abd Elmageed, Z.Y.; Nair, D.; Partyka, M.I.; Kadowitz, P.J.; Belmadani, S.; Matrougui, K. Modified multipotent stromal cells with epidermal growth factor restore vasculogenesis and blood flow in ischemic hind-limb of type II diabetic mice. Lab. Invest. 2010, 90, 985-996.
63. Lai, W.H.; Ho, J.C.; Chan, Y.C.; Ng, J.H.; Au, K.W.; Wong, L.Y.; Siu, C.W.; Tse, H.F. Attenuation of hind-limb ischemia in mice with endothelial-like cells derived from different sources of human stem cells. PLoS One 2013, 8, e57876.
64. Recchia, A.G.; Filice, E.; Pellegrino, D.; Dobrina, A.; Cerra, M.C.; Maggiolini, M. Endothelin-1 induces connective tissue growth factor expression in cardiomyocytes. J. Mol. Cell Cardiol. 2009, 46, 352-359.
65. Sugimoto, M.; Cutler, A.; Shen, B.; Moss, S.E.; Iyengar, S.K.; Klein, R.; Folkman, J.; Anand-Apte, B. Inhibition of EGF signaling protects the diabetic retina from insulin-induced vascular leakage. Am. J. Pathol. 2013, 183, 987-995.
66. Hewing, N.J.; Weskamp, G.; Vermaat, J.; Farage, E.; Glomski, K.; Swendeman, S.; Chan, R.V.; Chiang, M.F.; Khokha, R.; Anand-Apte, B.; Blobel, C.P. Intravitreal injection of TIMP3 or the EGFR inhibitor erlotinib offers protection from oxygen-induced retinopathy in mice. Invest. Ophthalmol. Vis. Sci. 2013, 54, 864-870.
67. Chan, A.K.; Kalmes, A.; Hawkins, S.; Daum, G.; Clowes, A.W. Blockade of the epidermal growth factor receptor decreases intimal hyperplasia in balloon-injured rat carotid artery. J. Vasc. Surg. 2003, 37, 644-649.
68. Shafi, S.; Lamb, D.; Modjtahedi, H.; Ferns, G. Periadventitial delivery of anti-EGF receptor antibody inhibits neointimal macrophage accumulation after angioplasty in a hypercholesterolaemic rabbit. Int. J. Exp. Pathol. 2010, 91, 224-234.
69. Lee, M.Y.; Martin, A.S.; Mehta, P.K.; Dikalova, A.E.; Garrido, A.M.; Datla, S.R.; Lyons, E.; Krause, K.-H.; Banfi, B.; Lambeth, J.D.; et al. Mechanisms of vascular smooth muscle NADPH oxidase 1 (Nox1) contribution to injury-induced neointimal formation. Arterioscler. Thromb. Vasc. Biol. 2009, 29, 480-487.
70. Takahashi, M.; Hayashi, K.; Yoshida, K.; Ohkawa, Y.; Komurasaki, T.; Kitabatake, A.; Ogawa, A.; Nishida, W.; Yano, M.; Monden, M.; Sobue, K. Epiregulin as a major autocrine/paracrine factor released from ERK-and p38MAPK-activated vascular smooth muscle cells. Circulation 2003, 108, 2524-2529.
71. Matsumoto, S.; Kishida, K.; Shimomura, I.; Maeda, N.; Nagaretani, H.; Matsuda, M.; Nishizawa, H.; Kihara, S.; Funahashi, T.; Matsuzawa, Y.; et al. Increased plasma HB-EGF associated with obesity and coronary artery disease. Biochem. Biophys. Res. Commun. 2002, 292, 781-786.
72. Sanchez-Vizcaino, E.; Vehi, C.; Camprecios, G.; Morcillo, C.; Soley, M.; Ramirez, I. Heparin-binding EGF-like growth factor in human serum. Association with high blood cholesterol and heart hypertrophy. Growth Factors 2009, 28, 98-103.
73. Jones, D.P. Redefining oxidative stress. Antioxid. Redox Signal. 2006, 8, 1865-1879.
74. Van der Vorst, E.P.; Keijbeck, A.A.; de Winther, M.P.; Donners, M.M. A disintegrin and metalloproteases: Molecular scissors in angiogenesis, inflammation and atherosclerosis. Atherosclerosis 2012, 224, 302-308.
75. Liu, X.; Gu, X.; Li, Z.; Li, X.; Li, H.; Chang, J.; Chen, P.; Jin, J.; Xi, B.; Chen, D.; et al. Neuregulin-1/erbB-activation improves cardiac function and survival in models of ischemic, dilated, and viral cardiomyopathy. J. Am. Coll. Cardiol. 2006, 48, 1438-1447.
76. Crone, S.A.; Zhao, Y.Y.; Fan, L.; Gu, Y.; Minamisawa, S.; Liu, Y.; Peterson, K.L.; Chen, J.; Kahn, R.; Condorelli, G.; et al. ErbB2 is essential in the prevention of dilated cardiomyopathy. Nat. Med. 2002, 8, 459-465.
77. Sysa-Shah, P.; Xu, Y.; Guo, X.; Belmonte, F.; Kang, B.; Bedja, D.; Pin, S.; Tsuchiya, N.; Gabrielson, K. Cardiac-specific over-expression of epidermal growth factor receptor 2 (ErbB2) induces pro-survival pathways and hypertrophic cardiomyopathy in mice. PLoS One 2012, 7, e42805.
78. Ozcelik, C.; Erdmann, B.; Pilz, B.; Wettschureck, N.; Britsch, S.; Hubner, N.; Chien, K.R.; Birchmeier, C.; Garratt, A.N. Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathy. Proc. Natl. Acad. Sci. USA 2002, 99, 8880-8885.
79. Nair, B.G.; Rashed, H.M.; Patel, T.B. Epidermal growth factor produces inotropic and chronotropic effects in rat hearts by increasing cyclic AMP accumulation. Growth Factors 1993, 8, 41-48.
80. Patel, T.B. Single transmembrane spanning heterotrimeric g protein-coupled receptors and their signaling cascades. Pharmacol. Rev. 2004, 56, 371-385.
81. Forster, K.; Kuno, A.; Solenkova, N.; Felix, S.B.; Krieg, T. The delta-opioid receptor agonist DADLE at reperfusion protects the heart through activation of pro-survival kinases via EGF receptor transactivation. Am. J. Physiol. Heart Circ. Physiol. 2007, 293, H1604-1608.
82. Fujio, Y.; Nguyen, T.; Wencker, D.; Kitsis, R.N.; Walsh, K. Akt promotes survival of cardiomyocytes in vitro and protects against ischemia-reperfusion injury in mouse heart. Circulation 2000, 101, 660-667.
83. Matsui, T.; Nagoshi, T.; Rosenzweig, A. Akt and PI 3-kinase signaling in cardiomyocyte hypertrophy and survival. Cell Cycle 2003, 2, 220-223.
84. Rajagopalan, V.; Zucker, I.H.; Jones, J.A.; Carlson, M.; Ma, Y.J. Cardiac ErbB-1/ErbB-2 mutant expression in young adult mice leads to cardiac dysfunction. Am. J. Physiol. Heart Circ. Physiol. 2008, 295, H543-H554.
85. Brown, N.J. Contribution of aldosterone to cardiovascular and renal inflammation and fibrosis. Nat. Rev. Nephrol. 2013, 9, 459-469.
86. Grossmann, C.; Krug, A.W.; Freudinger, R.; Mildenberger, S.; Voelker, K.; Gekle, M. Aldosterone-induced EGFR expression: Interaction between the human mineralocorticoid receptor and the human EGFR promoter. Am. J. Physiol. Endocrinol. Metab. 2007, 292, E1790-E1800.
87. Montezano, A.C.; Callera, G.E.; Yogi, A.; He, Y.; Tostes, R.C.; He, G.; Schiffrin, E.L.; Touyz, R.M. Aldosterone and angiotensin II synergistically stimulate migration in vascular smooth muscle cells through c-Src-regulated redox-sensitive RhoA pathways. Arterioscler. Thromb. Vasc. Biol. 2008, 28, 1511-1518.
88. Moriguchi, Y.; Matsubara, H.; Mori, Y.; Murasawa, S.; Masaki, H.; Maruyama, K.; Tsutsumi, Y.; Shibasaki, Y.; Tanaka, Y.; Nakajima, T.; et al. Angiotensin II-induced transactivation of epidermal growth factor receptor regulates fibronectin and transforming growth factor-beta synthesis via transcriptional and posttranscriptional mechanisms. Circ. Res. 1999, 84, 1073-1084.
89. Zhai, P.; Galeotti, J.; Liu, J.; Holle, E.; Yu, X.; Wagner, T.; Sadoshima, J. An angiotensin II type 1 receptor mutant lacking epidermal growth factor receptor transactivation does not induce angiotensin II-mediated cardiac hypertrophy. Circ. Res. 2006, 99, 528-536.
90. Kagiyama, S.; Qian, K.; Kagiyama, T.; Phillips, M.I. Antisense to epidermal growth factor receptor prevents the development of left ventricular hypertrophy. Hypertension 2003, 41, 824-829.
91. Messaoudi, S.; Zhang, A.D.; Griol-Charhbili, V.; Escoubet, B.; Sadoshima, J.; Farman, N.; Jaisser, F. The epidermal growth factor receptor is involved in angiotensin II but not aldosterone/salt-induced cardiac remodelling. PLoS One 2012, 7, e30156.
92. Methner, C.; Donat, U.; Felix, S.B.; Krieg, T. Cardioprotection of bradykinin at reperfusion involves transactivation of the epidermal growth factor receptor via matrix metalloproteinase-8. Acta Physiol. (Oxf) 2009, 197, 265-271.
93. Belmadani, S.; Palen, D.I.; Gonzalez-Villalobos, R.A.; Boulares, H.A.; Matrougui, K. Elevated epidermal growth factor receptor phosphorylation induces resistance artery dysfunction in diabetic db/db mice. Diabetes 2008, 57, 1629-1637.
94. Benter, I.F.; Yousif, M.H.; Griffiths, S.M.; Benboubetra, M.; Akhtar, S. Epidermal growth factor receptor tyrosine kinase-mediated signalling contributes to diabetes-induced vascular dysfunction in the mesenteric bed. Br. J. Pharmacol. 2005, 145, 829-836.
95. Yousif, M.H.; Benter, I.F.; Akhtar, S. The role of tyrosine kinase-mediated pathways in diabetes-induced alterations in responsiveness of rat carotid artery. Auton. Autacoid Pharmacol. 2005, 25, 69-78.
96. Matrougui, K. Diabetes and microvascular pathophysiology: Role of epidermal growth factor receptor tyrosine kinase. Diabetes Metab. Res. Rev. 2010, 26, 13-16.
97. Benter, I.F.; Benboubetra, M.; Hollins, A.J.; Yousif, M.H.; Canatan, H.; Akhtar, S. Early inhibition of EGFR signaling prevents diabetes-induced up-regulation of multiple gene pathways in the mesenteric vasculature. Vascul. Pharmacol. 2009, 51, 236-245.
98. Clynes, R.A.; Towers, T.L.; Presta, L.G.; Ravetch, J.V. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat. Med. 2000, 6, 443-446.
99. Di Cosimo, S. Heart to heart with trastuzumab: A review on cardiac toxicity. Target. Oncol. 2011, 6, 189-195.
100. Orphanos, G.S.; Ioannidis, G.N.; Ardavanis, A.G. Cardiotoxicity induced by tyrosine kinase inhibitors. Acta Oncol. 2009, 48, 964-970.